The pharmacokinetics of ondansetron after intravenous injection in healthy volunteers phenotyped as poor or extensive metabolisers of debrisoquine.

The pharmacokinetics of the 5‐HT3 receptor antagonist ondansetron following an 8 mg i.v. dose were investigated in 12 subjects previously phenotyped with debrisoquine. Six subjects were poor metabolisers (debrisoquine metabolic ratios 29‐131) and six were extensive metabolisers (debrisoquine metabolic ratios 0.45‐3.4). There was no significant difference in AUC, Cmax, CL or t1/2 between the poor and extensive metabolisers. It is concluded that ondansetron clearance is not mediated exclusively by cytochrome P‐450 2D6.

DOI: 10.1111/j.1365-2125.1994.tb04294.x

View this article

• Full article (html)
• Enhanced article (html)
• PDF
• References